Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Johnson and Johnson
Merck
Mallinckrodt
Express Scripts

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Teva Womens Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Teva Womens
International Patents:24
US Patents:3
Tradenames:14
Ingredients:8
NDAs:8

Drugs and US Patents for Teva Womens

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens ADDERALL 7.5 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-011 Aug 31, 2000 DISCN Yes No 6,384,020*PED   See Pricing Y   See Pricing
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-002 Jul 31, 1992 DISCN Yes No   See Pricing   See Pricing
Teva Womens REVIA naltrexone hydrochloride TABLET;ORAL 018932-001 Nov 20, 1984 DISCN No No   See Pricing   See Pricing
Teva Womens PREFEST estradiol; norgestimate TABLET;ORAL 021040-001 Oct 22, 1999 DISCN Yes No 6,747,019   See Pricing   See Pricing
Teva Womens VIVACTIL protriptyline hydrochloride TABLET;ORAL 016012-002 Approved Prior to Jan 1, 1982 DISCN No No   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Womens

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-002 Jul 31, 1992 4,258,062*PED   See Pricing
Teva Womens PREFEST estradiol; norgestimate TABLET;ORAL 021040-001 Oct 22, 1999 5,108,995   See Pricing
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-001 Jul 31, 1992 4,258,062*PED   See Pricing
Teva Womens PREFEST estradiol; norgestimate TABLET;ORAL 021040-001 Oct 22, 1999 5,382,573   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA WOMENS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg, 30 mg ➤ Subscribe 2009-11-18

Supplementary Protection Certificates for Teva Womens Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1380301 2009C/007 Belgium   See Pricing PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
2316456 1790064-8 Sweden   See Pricing PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456 LUC00054 Luxembourg   See Pricing PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456 2017/059 Ireland   See Pricing PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326
1453521 93156 Luxembourg   See Pricing PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Colorcon
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.